Azenta, Inc. (AZTA)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 4
Do Nothing: the input snapshot price 37.4 is above the $25 strategy ceiling, and qualitativeScore 2 is below the required floor of 3.
Company overview
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
Fundamental
fairAzenta shows strong liquidity but inconsistent profitability and growth, with ongoing internal-control weaknesses.
Azenta’s recent SEC filings show solid liquidity and no explicit going-concern red flags, but profitability is weak and volatile due to a large goodwill impairment and prior-year one-offs (tax benefit/discontinued-ops swings). Trailing free cash flow is modest (about a half-percent yield), so valuation depends on a future margin recovery more than today’s cash generation. Net result: financially safe, but fundamentally mixed until profitability and cash conversion improve.
Sentiment
weakMedia sentiment is mildly positive post-earnings, but retail interest is low and the catalyst calendar is thin.
Azenta announced a CEO/board leadership transition today (interim President/CEO appointed; announced), adding near-term governance uncertainty while the last ~14d media tone stayed only mildly positive and cooled versus a more bullish 30–90d baseline (polarity_score ≈ +0.13 vs ≈ +0.38). Legal screening shows no regulator-confirmed action; the visible items are plaintiff-law-firm “investigation”/solicitation-style headlines that function more as low-confidence overhang than a confirmed catalyst.
Technical
goodAzenta is in a strong uptrend above key averages but currently overbought.
As of 2026-08-21, AZTA has a strong short-term breakout: price 37.4 is above SMA20/50/200 (31.99/27.84/28.19), EMA9/21 (34.63/32.34), and daily VWAP 36.87, while MACD 2.44 is above signal 2.10 and above zero and ADX 61.74 confirms trend strength. Liquidity is strong at about $22.29M average dollar volume. I score it a 4, not a 5, because RSI14 78.71 and Williams %R -1.07 show short-term extension and the SMA50 still sits slightly below the SMA200.
You’re looking at 2026-08-24 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.